Trial Profile
Decitabine in Combination With Chidamide, Homoharringtonine and Ara-c (DCHA) as Postremission Therapy for Acute Myeloid Leukemia With t(8;21) :A Multicenter Prospective Study
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Decitabine (Primary) ; Omacetaxine mepesuccinate (Primary) ; Tucidinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 06 Mar 2018 New trial record